Porcine recombinant factor VIII: An additional weapon to handle anti-factor VIII antibodies

Pier Mannuccio Mannucci, Massimo Franchini

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.

Original languageEnglish
Pages (from-to)365-368
Number of pages4
JournalBlood Transfusion
Volume15
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Weapons
Factor VIII
Swine
Antibodies
Hemophilia A
Autoantibodies
Hemorrhage

Keywords

  • Bleeding
  • Haemophilia A
  • Inhibitors
  • Obizur
  • Porcine recombinant FVIII

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

Cite this

Porcine recombinant factor VIII : An additional weapon to handle anti-factor VIII antibodies. / Mannucci, Pier Mannuccio; Franchini, Massimo.

In: Blood Transfusion, Vol. 15, No. 4, 2017, p. 365-368.

Research output: Contribution to journalReview article

@article{7344d6e14d374f88ac6d68a769acd0c1,
title = "Porcine recombinant factor VIII: An additional weapon to handle anti-factor VIII antibodies",
abstract = "This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.",
keywords = "Bleeding, Haemophilia A, Inhibitors, Obizur, Porcine recombinant FVIII",
author = "Mannucci, {Pier Mannuccio} and Massimo Franchini",
year = "2017",
doi = "10.2450/2016.0030-16",
language = "English",
volume = "15",
pages = "365--368",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "Edizioni SIMTI",
number = "4",

}

TY - JOUR

T1 - Porcine recombinant factor VIII

T2 - An additional weapon to handle anti-factor VIII antibodies

AU - Mannucci, Pier Mannuccio

AU - Franchini, Massimo

PY - 2017

Y1 - 2017

N2 - This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.

AB - This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.

KW - Bleeding

KW - Haemophilia A

KW - Inhibitors

KW - Obizur

KW - Porcine recombinant FVIII

UR - http://www.scopus.com/inward/record.url?scp=85021818761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021818761&partnerID=8YFLogxK

U2 - 10.2450/2016.0030-16

DO - 10.2450/2016.0030-16

M3 - Review article

AN - SCOPUS:85021818761

VL - 15

SP - 365

EP - 368

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 4

ER -